Merck has been quietly making moves worldwide to position molnupiravir as the standard early-onset, orally-administered antiviral treatment for COVID-19. TrialSite has reported that Merck’s teams…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.